[Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases]. / Les effets indésirables du Glucantime par voie générale, dans le traitement de la leishmaniose cutanée: à propos de 15 cas.
Tunis Med
; 88(1): 9-11, 2010 Jan.
Article
em Fr
| MEDLINE
| ID: mdl-20415206
ABSTRACT
BACKGROUND:
Leishmaniasis is wide spread parasitic disease considered to be endemic in 88 countries in both old and new world. The standard treatment remains Meglumine antimoniate.AIM:
We study the side effects of systemic meglumine antimoniate in cutaneous leishmaniasis.METHODS:
We conduct a retrospective study covering 3-year period (2002- 2005). All medical reports of cutaneous leishmaniasis treated by systemic Meglumine antimoniate are reviewed.RESULTS:
The study comprise 63 patients all treated by systemic meglumine antimoniate at the dose of 60 mg/kg/day for 10-15 days. Side effects were noted in 15 cases (12 females and 3 males). The subject's age range from 11 to 78 years. Stibio-intolerance (fever, rash, arthralgia, abdominal pain) was observed in 12 cases and stibiotoxicity in 3 cases precordialgies 1 case, hyperamylasemia and increase liver enzyme 1 case, pancytopenia, renal and hepatic failure leading to death 1 case, skin eruption 7 cases, pruritus and erythema in the site of injection 5 cases, urticaria 1 case. Meglumine antimoniate was stopped in 13 cases.CONCLUSION:
Meglumine antimoniate is the generally recommended treatment of cutaneous leishmaniasis. In spite of the rarity of Glucantime's side effects, we recommend a careful survey especially in older patients.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Compostos Organometálicos
/
Leishmaniose Cutânea
/
Meglumina
/
Antiprotozoários
Tipo de estudo:
Observational_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Animals
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Fr
Revista:
Tunis Med
Ano de publicação:
2010
Tipo de documento:
Article